Matinas BioPharma Holdings, Inc. 8-K

What Happened

• Matinas BioPharma Holdings, Inc. (MTNB) filed a Current Report on Form 8-K on June 26, 2026 reporting a notice under Item 3.01 concerning a delisting or failure to satisfy a NYSE American continued listing rule or standard.
• In accordance with NYSE American procedures, the company issued a press release on June 26, 2026 discussing the matters disclosed (Item 8.01). The press release is attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: June 26, 2026 (Form 8-K).
• Items reported: 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard) and 8.01 (Other Events — press release).
• Exhibit included: 99.1 — Press Release dated June 26, 2026; 104 — Cover Page Interactive Data File (Inline XBRL).
• The filing contains forward-looking statements about the company’s plans to regain compliance with NYSE American listing standards and refers investors to the risk disclosures in Matinas’ Form 10-K for the year ended December 31, 2025.

Why It Matters

• A notice related to NYSE American listing standards is material because it may affect where and how the company’s shares trade, and could influence liquidity and investor confidence.
• The company has issued a press release and included forward-looking statements about efforts to regain compliance; investors should read the press release and the company’s 2025 Form 10-K risk disclosures for more details and context.
• Shareholders and prospective investors may want to monitor future filings and company communications for updates on any compliance plan, timelines, or outcomes.